ENDRA Life Sciences Inc. (NDRA) stock
NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
$4.04+0.12 (+2.93%)
Close on Nov 18, 2026Market cap $6.05MP/E –Yield –
ENDRA Life Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ENDRA Life Sciences's operating income for the twelve months ending Jun 30, 2026 was -$6.65M. For fiscal 2025 it was -$5.76M. The highest annual figure on record is -$1.79M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.76M | – |
| FY2024 | Dec 31, 2024 | -$10.82M | – |
| FY2023 | Dec 31, 2023 | -$10.52M | – |
| FY2022 | Dec 31, 2022 | -$13.16M | – |
| FY2021 | Dec 31, 2021 | -$11.50M | – |
| FY2020 | Dec 31, 2020 | -$11.50M | – |
| FY2019 | Dec 31, 2019 | -$10.84M | – |
| FY2018 | Dec 31, 2018 | -$9.02M | – |
| FY2017 | Dec 31, 2017 | -$4.63M | – |
| FY2016 | Dec 31, 2016 | -$1.79M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.62M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.78M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.46M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.13M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.57M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.65M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.26M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.89M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.10M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.13M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.64M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.75M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.00M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.36M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.82M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.84M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.30M | – |
| Q3 FY2017 | Sep 30, 2017 | -$910.93K | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.06M | – |
| Q1 FY2017 | Mar 31, 2017 | -$360.70K | – |
| Q4 FY2016 | Dec 31, 2016 | -$318.88K | – |
| Q3 FY2016 | Sep 30, 2016 | -$605.11K | – |
See a number that looks wrong?